Connect to share and comment

Galapagos, GSK successfully conclude phase 2a study of skin disease drug

BRUSSELS (Reuters) - Belgian biotech group Galapagos NV on Thursday said it has successfully concluded the phase 2a study of a skin disease drug it is developing with Britain's GlaxoSmithKline PLC. Galapagos tested drug GSK2586184 on 66 patients with chronic psoriasis and observed a 75 percent improvement in significantly more patients than in the placebo group. GSK, which owns the drug's commercial rights, will decide whether to proceed with clinical trials, Galapagos said in a statement.

Mexican Nobel laureate inducted into French Legion of Honor

Mexico City, Apr 11 (EFE).- Mexican scientist Mario Molina, winner of the 1995 Nobel Prize in Chemistry, was decorated with the Knight medal of the Legion of Honor by French President Francois Hollande in recognition of his services to humanity. The induction ceremony took place at Club France in the Mexican capital, where Hollande arrived Thursday for an official visit to the Aztec nation.

Exclusive: Heart docs seek curbs on kidney-zapping hypertension devices

By Ransdell Pierson and Bill Berkrot (Reuters) - Several leading U.S. and European heart doctors are calling for curbs, or even a moratorium, on using devices meant to lower blood pressure by zapping kidney arteries, following a surprising failure of the technology in a clinical trial.

GSK links with top labs on 'big data' drug project

By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline is linking with two top bioscience centres on an open-access research project to tap into "big data" generated by gene research, in a move highlighting how drug companies are learning to share. The new public-private Centre for Therapeutic Target Validation (CTTV) is being created by GSK working alongside the Wellcome Trust Sanger Institute and the European Bioinformatics Institute, both of which are based in Cambridge, England.

Russia's Yakov Sinai wins Abel mathematics prize

Russian mathematician Yakov Sinai won the prestigious Abel mathematics prize for his work in dynamical systems and mathematical physics, the Norwegian Academy of Science and Letters said Wednesday. Yakov, 78, teaches at US Princeton University and at the Landau Institute for Theoretical Physics in Moscow. "Yakov Sinai is one of the most influential mathematicians of the twentieth century, the Norwegian academy said in a statement. "He has achieved numerous groundbreaking results in the theory of dynamical systems, in mathematical physics and in probability theory."

'Green Revolutionary' Borlaug honored in US Capitol

Norman Borlaug, whose work on disease-resistant wheat is credited with saving up to one billion lives, on Tuesday received his latest posthumous honor -- a statue in the US Capitol. On what would have been Borlaug's 100th birthday, lawmakers unveiled a seven-foot (two-meter) bronze likeness of the father of the "Green Revolution" in the National Statuary Hall in the heart of the Capitol where each state dedicates two statues.

U.S. lawmakers ask Gilead about Sovaldi pricing

(Reuters) - U.S. lawmakers have asked Gilead Sciences Inc for a briefing on the price of its new hepatitis C drug Sovaldi, which can cost more than $80,000 per patient. A letter to Gilead from Democrats in the House Energy & Commerce Committee asks for information on Sovaldi discounts on the recently approved medicine to payors and patients. Sovaldi, seen as a breakthrough in the treatment of the serious liver disease, costs about $84,000 per patient.

NFL: Panthers Newton to undergo ankle surgery

Carolina Panthers quarterback Cam Newton will undergo surgery Wednesday on his sore ankle, the National Football League team announced. The Panthers' team doctor will conduct the surgery to alleviate soreness that Newton has suffered from since the end of the last season. The surgery involves tightening the ankle ligaments which have become stretched. The 24-year-old Newton's rehab is expected to last four months which would make him available in time for the beginning of training camp.

Police back in the dock at Pistorius trial

Oscar Pistorius's defence lawyer grilled a police forensics expert for a second day Thursday, questioning his qualifications in a bid to discredit key evidence from the night the Paralympian shot dead his girlfriend. Barry Roux resumed a searing cross-examination of Colonel Gerhard Vermeulen, hoping to rubbish his testimony that could indicate the double-amputee sprinter lied about how events unfolded on February 14, 2013.

Police admit Pistorius evidence may be tainted

Oscar Pistorius's defence lawyer Wednesday forced police to admit they had mishandled key evidence, as the Olympian battled to discredit forensics that could prove he lied about the night his girlfriend was killed. In his testimony Colonel Gerhard Vermeulen admitted the toilet door in the athlete's apartment was not handled with care and potentially important evidence was missed at the crime scene, which could have far-reaching consequences for the prosecution's case.
Syndicate content